In our analysis, the high correlation between the immune-related gene signature-based risk score and the IL-6/JAK/Stat3 pathway highlighted the tumour-promoting effect of the IL-6/JAK/Stat3 pathway in early-stage LUAD [4, 26]. The gene discussed is STAT3; the disease is neoplasm.